Suppr超能文献

[6]-姜辣素衍生的半合成化合物SSi6在三阴性乳腺癌异种移植模型中抑制肿瘤生长和转移扩散。

[6]-Gingerol-Derived Semi-Synthetic Compound SSi6 Inhibits Tumor Growth and Metastatic Dissemination in Triple-Negative Breast Cancer Xenograft Models.

作者信息

Luna-Dulcey Liany, Almada da Silva James, Jimenez-Renard Veronica, Caleiras Eduardo, Mouron Silvana, Quintela-Fandino Miguel, Cominetti Marcia R

机构信息

Laboratory of Biology of Aging (LABEN), Department of Gerontology, Federal University of São Carlos (UFSCar), CEP 13565-905 São Carlos-SP, Brazil.

Department of Pharmacy, Federal University of Sergipe (UFS), CEP 49400-000, Av. Gov. Marcelo Deda, 330-São José, Lagarto-SE, Brazil.

出版信息

Cancers (Basel). 2021 Jun 8;13(12):2855. doi: 10.3390/cancers13122855.

Abstract

Breast cancer metastasis is the most common cause of cancer death in women worldwide. Triple-negative breast cancers (TNBC) form a heterogeneous group of tumors that have higher relapse rates and poorer survival compared to other breast cancer subtypes. Thus, this work reports the antitumor and antimetastatic activities of a [6]-gingerol-derived semi-synthetic compound named SSi6 on MDA-MB-231 TNBC cells using xenograft models. SSi6 did not cause toxic effects as demonstrated by body weight and hematological and histological evaluations. From the orthotopic xenograft model, we demonstrated that SSi6 slows and inhibits the growth of the primary tumor, as well as prevents metastatic spontaneous progression from lymph nodes to the lungs. Moreover, a second xenograft model with resection of the primary tumor showed that SSi6 also blocks the progression of metastases from the lymph nodes to other visceral organs. Taken together, our results demonstrate that SSi6 is a promising compound to be investigated in other preclinical and clinical models to be applied as a complementary therapy for TNBC.

摘要

乳腺癌转移是全球女性癌症死亡的最常见原因。三阴性乳腺癌(TNBC)是一组异质性肿瘤,与其他乳腺癌亚型相比,其复发率更高,生存率更低。因此,本研究使用异种移植模型报告了一种名为SSi6的[6]-姜酚衍生半合成化合物对MDA-MB-231 TNBC细胞的抗肿瘤和抗转移活性。体重、血液学和组织学评估表明,SSi6没有产生毒性作用。从原位异种移植模型中,我们证明了SSi6可减缓并抑制原发性肿瘤的生长,并防止从淋巴结到肺部的转移自发进展。此外,第二个切除原发性肿瘤的异种移植模型表明,SSi6还可阻断从淋巴结到其他内脏器官的转移进展。综上所述,我们的结果表明,SSi6是一种有前景的化合物,有望在其他临床前和临床模型中进行研究,作为TNBC的辅助治疗药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa46/8228746/f9f8e90d95e6/cancers-13-02855-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验